Thanks for the heads up!

Just for kicks I asked https://www.perplexity.ai the following question and within seconds received an amazingly comprehensive answer based on 8 high quality references listed below.
If anyone is wondering about the impact of AI in the field of PCa…look no further! AI's value in reducing one's research time to obtain high quality answers regarding complex subjects in almost all fields is absolutely incredible!

Q: How does the accuracy of the PSE test compare to the MPS2 test?

A: Based on the available information, we can compare the accuracy of the EpiSwitch Prostate Screening (PSE) Test and the MyProstateScore 2.0 (MPS2) test as follows:

Accuracy Comparison

EpiSwitch PSE Test
• Improves predictive accuracy from 55% (PSA alone) to 94%.
• Shows a specificity of 97% and sensitivity of 86%.

MyProstateScore 2.0 (MPS2) Test
• Demonstrates a sensitivity of 95% for Grade Group 2 (GG2) prostate cancers.
• Shows a sensitivity of 99% for cancers that were Grade Group 3 (GG3) or higher.
• Has negative predictive values of 95% to 99% for cancers of GG2 or greater, and 99% for cancers of GG3 or greater.

Performance Metrics

Area Under the Receiver Operating Characteristic (AUC) Curve
• MPS2: 0.81
• MPS2+ (including prostate volume): 0.82.

These values are significantly higher than other tests mentioned in the study:
• PSA alone: 0.60
• Prostate Cancer Prevention Trial risk calculator: 0.66
• Prostate Health Index (PHI): 0.77
• Original MPS model: 0.74.

Reduction in Unnecessary Biopsies

The MPS2 test shows potential to reduce unnecessary biopsies:
• 35% to 42% reduction in the initial biopsy population
• 46% to 51% reduction in the repeat biopsy population.

While both tests show impressive accuracy, the MPS2 test appears to have slightly higher sensitivity, especially for higher-grade cancers. However, it's important to note that these tests were not directly compared in the same study, so a definitive comparison is challenging. The MPS2 test seems to have more detailed performance data available in the provided search results, including its ability to reduce unnecessary biopsies. Both tests represent significant improvements over PSA testing alone and could potentially help reduce unnecessary biopsies while maintaining high sensitivity for detecting clinically significant prostate cancers.

References cited in perplexity AI’s answer:
https://www.health.harvard.edu/blog/new-urine-test-may-help-some-men-with-elevated-psa-avoid-biopsy-202405063038
https://www.nih.gov/news-events/nih-research-matters/urine-test-identifies-high-risk-prostate-cancers
https://prevention.cancer.gov/news-and-events/blog/improved-prostate-cancer-biomarker-test-may-help-men-avoid-unnecessary-biopsy
https://jamanetwork.com/journals/jamaoncology/fullarticle/2817657
https://pmc.ncbi.nlm.nih.gov/articles/PMC11190811/
https://news.vumc.org/2024/04/18/new-urine-test-has-higher-diagnostic-accuracy-for-prostate-cancer/
https://www.lynxdx.com/2024/04/news/mps2-clinically-validated-jama-oncology/
https://cancerworld.net/new-prostate-cancer-blood-test-psa-epigenetic/

And then there is the Artera.ai test, where you send images of your biopsy and they give you a lot of information about future treatment. The test takes 2 to 3 days to get results. It has been approved by the NCCN. This goes past the decipher test in the information that is supplied.

From Artera
The ArteraAI Prostate Test offers prognostic and predictive insights. The prognostic information includes a score indicating various risks for you, like metastasis (cancer spreading) and survival, while predictive information informs whether you are likely to benefit from a specific therapy, e.g., a hormone therapy or androgen deprivation therapy (ADT).